First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial - Matsubara, Nobuaki; Azad, Arun A; Agarwal, Neeraj; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C C; Jones, Robert J; Zschäbitz, Stefanie; Oldenburg, Jan; Shore, Neal D; Dunshee, Curtis; et al. (The lancet. Oncology, 2025)
Online verfügbar 31 March 2025, Version des Artikels 31 March 2025